Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-11-03 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于变更审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the company's audit firm. It details the dismissal of the previous auditor and the appointment of a new auditor for the company's 2019 annual audit. There is no financial data or audit report included, only information about the change in audit institution. This fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. The document length is short and it is not a report publication announcement or certification. Therefore, the classification is AR with high confidence. FY 2019
2019-11-03 Chinese
上市公司股权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a detailed compliance self-check form related to a company's equity incentive plan, including numerous compliance questions, regulatory references, and internal control checks. It does not contain financial statements or performance data but rather a checklist and confirmations about compliance with regulations and internal policies. The document length is 4056 characters, which is relatively short and more consistent with a regulatory or compliance filing rather than a full financial report. There is no indication that this is an annual report, interim report, earnings release, or any other financial report type. It is also not a simple announcement or certification but a compliance checklist. Given the nature of the content, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2019-11-03 Chinese
独立董事公开征集委托投票权报告书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an "Independent Director Public Solicitation of Proxy Voting Rights Report" for a specific shareholders' meeting (the 2019 fourth extraordinary general meeting). It details the solicitation process for proxy voting rights by an independent director, including legal disclaimers, procedures for shareholders to submit proxy authorizations, and voting instructions on specific agenda items related to a stock option incentive plan. The document references the China Securities Regulatory Commission and Shenzhen Stock Exchange, indicating regulatory compliance. It is not a financial report, earnings release, or management discussion but rather a formal solicitation and proxy voting report related to a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it concerns proxy voting rights solicitation and voting instructions for shareholder resolutions. The document length is under 5,000 characters, but it contains substantive content about the proxy solicitation, not merely an announcement of a report publication. Therefore, the best classification is DVA with high confidence.
2019-11-03 Chinese
《公司章程》修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing amendments to the company's Articles of Association (公司章程), specifically reflecting changes in registered capital and share capital due to stock option exercises. It mentions that the amendments were approved by the board and require shareholder approval. This type of document relates to governance and internal company rules rather than financial results or announcements. It is not a full annual or interim report, nor an announcement of voting results or capital changes per se, but a governance document detailing changes to the company's constitution. Therefore, the most appropriate classification is Governance Information (CGR). The document length is short but contains substantive governance content, not just an announcement or notice.
2019-11-03 Chinese
公司章程（2019年11月）
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of 健帆生物科技集团股份有限公司, which is a detailed governance document outlining the company's organizational structure, shareholder rights, board responsibilities, and meeting procedures. It references compliance with Chinese Company Law and Securities Law, and includes detailed provisions on shareholder meetings, voting, capital structure, and management roles. This type of document is a governance framework rather than a financial report, earnings release, or announcement. It is not a report publication announcement or a regulatory filing of a different nature. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full governance document, not a brief announcement or summary.
2019-11-03 Chinese
中航证券有限公司关于公司以现金收购及增资方式取得深圳市家云智能科技有限公司10%股权暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中航证券有限公司) regarding a related-party transaction where 健帆生物科技集团股份有限公司 acquires a 10% equity stake in 深圳市家云智能科技有限公司 through cash acquisition and capital increase. It includes transaction overview, related parties' information, transaction pricing, agreements, governance, and impact on the listed company. The document is not a financial report, earnings release, or management discussion but a formal verification and opinion on a specific transaction, fulfilling regulatory requirements for disclosure of related-party transactions and compliance with stock exchange rules. This type of document is best classified as a Regulatory Filing (RNS) because it is a compliance and disclosure document related to a corporate transaction and not a standalone audit report, annual report, or capital update. The document length is over 10,000 characters and contains substantive content, not just an announcement or certification letter, so it is not RPA or a certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-10-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.